Afinitor

Afinitor (everolimus) is indicated for the treatment of advanced renal cell carcinoma that has progressed during or after VEGF-targeted therapy.

Everolimus inhibits mTOR (mammalian target of rapamycin), a serine/threonine kinase that regulates a variety of key cellular processes and is upregulated in several types of cancer.

In a Phase III trial in 416 patients with metastatic renal cell carcinoma whose disease had progressed despite VEGF-targeted treatment with sunitinib and/or sorafenib, the median duration of progression-free survival was 4.9 months on everolimus compared with 1.9 months on placebo.

Afinitor is not recommended for patients with severe hepatic impairment.

View Afinitor drug record

Further information: Novartis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases